More often than not, it’s the strategy that comes before the submission.

When a regulatory process is delayed, the first instinct is often to blame ANVISA. After all, the Agency operates in a highly demanding environment, handling complex reviews and a growing volume of submissions.

In reality, however, many delays don’t begin during ANVISA’s review.

They begin months earlier — during regulatory planning.

And that’s where companies often lose valuable time, increase costs, and compromise their market strategy.

Submission is only one step in the process

Most companies dedicate significant effort to preparing the submission package: collecting documentation, organizing technical files, and ensuring every required form is completed.

But even a perfectly assembled dossier cannot compensate for a poorly designed regulatory strategy.

When key decisions are made without aligning regulatory, technical, commercial, and operational perspectives, the consequences often include:

• Technical deficiencies and Agency questions;
• Documentation rework;
• Additional testing requirements;
• Incorrect regulatory classification;
• Delays in product launch.

In many cases, these issues could have been prevented long before the submission was prepared.

Regulatory strategy begins well before documentation

Successful regulatory projects usually start with strategic planning during product development—not when the registration dossier is being assembled.

That planning answers critical questions such as:

• What is the most appropriate regulatory pathway?
• Does the product already comply with Brazilian requirements?
• Which studies will actually be required?
• Can existing data or equivalence be leveraged?
• Is the manufacturer’s documentation ready for the Brazilian market?
• Is the regulatory timeline aligned with the commercial launch plan?

The answers to these questions directly influence costs, timelines, and the overall likelihood of approval.

The cost of late decisions

When strategic regulatory decisions are postponed, the impact can be significant.

A simple change in product classification may require new testing.

Incomplete documentation may interrupt the review process.

An inadequate choice of manufacturer, distributor, or legal representative can delay an entire market entry strategy.

In highly competitive industries, losing a few months can mean losing market share, delaying revenue generation, and increasing operational costs.

Experience reduces uncertainty

At Register Medical Group, our work doesn’t begin when the submission is filed.

It begins much earlier.

We work alongside our clients from the earliest stages of product planning, helping identify regulatory risks, define the optimal pathway, and build a strategy that increases predictability throughout the entire registration process.

The result is fewer surprises, fewer regulatory setbacks, and more efficient submissions.

Because, in many cases, the real challenge isn’t ANVISA.

It’s the strategy that comes before the protocol.

Strategy saves months.

At Register Medical Group, we help national and international companies transform complex regulatory requirements into structured, predictable, and efficient market access strategies.

Before submitting, build the right strategy.